![GenSight Biologics S.A. logo](/logos/SIGHT.PA.webp)
GenSight Biologics S.A.
EPA:SIGHT.PA
Overview | Financials
Company Name | GenSight Biologics S.A. |
Symbol | SIGHT.PA |
Currency | EUR |
Price | 0.37 |
Market Cap | 40,439,101 |
Dividend Yield | 0% |
52-week-range | 0.282 - 0.919 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Bernard Gilly Ph.D. |
Website | https://www.gensight-biologics.com |
An error occurred while fetching data.
About GenSight Biologics S.A.
GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010),
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD